A new study suggests that ultrasound technology could allow for the earlier detection of inflammation, and therefore earlier treatment of inflammatory diseases, in patients with early joint pain.
Diagnosing inflammatory diseases such as rheumatoid arthritis early and initiating treatment with disease-modifying anti-rheumatic drugs is important in slowing disease progression and joint damage. However, it has been difficult for clinicians to identify which patients with joint pain will develop inflammatory arthritis (IA) prior to the clinical appearance of inflammation of the synovial membrane, or synovitis. A new study, published in Arthritis Research and Therapy, suggests that ultrasound technology could allow for the earlier detection of inflammation, and therefore earlier treatment of inflammatory diseases, in patients with early joint pain.
The multi-center prospective cohort study followed patients (n = 196) who had inflammatory joint complaints that could not be explained by other conditions, for a period of 1 year. Data collected at baseline and at 6-month and 12-month follow-ups included swollen joint count, tender joint count, diagnosis, medications, and laboratory values including rheumatoid factor and erythrocyte sedimentation rate.
At baseline, ultrasound examiners used a high-frequency linear array probe to evaluate 26 joints using both greyscale and power Doppler imaging, and found that 72 patients with joint pain (37%) had synovitis, as identified on the greyscale image, and 29 patients had a positive power Doppler signal. After 1 year of follow-up, 16% of patients with joint pain developed IA, and ultrasound had shown synovitis in 59% of those patients at the time of the baseline scan.
The researchers also found the following with respect to ultrasound’s predictive value:
The authors concluded that a positive power Doppler signal is associated with the development of IA after 1 year, and that ultrasounds can also help to identify which patients with joint pain will not develop IA. Further research is necessary, they write, to confirm their results regarding the diagnostic value of ultrasound to predict progression from early joint pain to an inflammatory disease.
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More